Daily Brief Health Care: Dyadic International , Revvity, Sunway Healthcare Holdings and more

• Dyadic International, Inc. is a global biotechnology company based in Jupiter, Florida, developing and commercializing precision-engineered, animal-free recombinant proteins and enzymes using proprietary microbial expression platforms.
• The company’s common stock has been listed on Nasdaq under the symbol “DYAI” since April 17, 2019, with 40,063,703 shares outstanding as of September 10, 2026.
• The company has a history of net losses and $6.0 million in 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Revvity is moving to deepen its position in human-relevant drug discovery with the planned acquisition of France-based Human Cell Design, a biotechnology company specializing in human cell models for diabetes, obesity, and other metabolic diseases.
• Announced on September 9, 2026, the transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, while financial terms remain undisclosed.
• The acquisition would add Human Cell Design’s pancreatic beta cell models to Revvity’s Life Sciences portfolio, extending its capabilities in GLP-1 and broader metabolic drug screening while creating potential applications in regenerative medicine and cell-based therapies.

• Fast Gestation Replicability: Sunway Healthcare Group demonstrates sector-leading hospital ramp-up times, with its newest facilities—SMC Damansara and SMC Ipoh—reaching operational breakeven in under 12 to 15 months (achieving pre-tax and EBITDA breakeven respectively in January 2026). This significantly outperforms the private healthcare industry average of 3 to 5 years.
• High Revenue Intensity Dominance: Sunway boasts the highest average revenue per licensed bed in Malaysia at RM 1.3 million, driven by a high-acuity quaternary care model and specialized centers of excellence. This pricing power, alongside the captive nursing pipeline from Sunway University, forms a robust competitive moat against regional peers IHH Healthcare and KPJ Healthcare.
• Post-IPO Capital Structure Strength: Following its March 18, 2026 listing, Sunway’s net gearing improved from 42% to 11%. This fortifies its balance sheet ahead of the September 18, 2026 lock-up expiration, positioning the company to fund its 3,400-bed 2032 expansion pipeline entirely through organic cash flows and green debt, with minimal reliance on dilutive equity.